All In Biotech

Drug Trial Radar · NCT05399888

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

416

Actual

Start

Aug 24, 2022

Primary completion

Mar 11, 2026

Study completion Jun 6, 2028

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called diranersen (BIIB080). The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if diranersen can slow the worsening of AD more than placebo. It will focus on what dose of diranersen slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. * Clinicians use the CDR-SB to measure several categories of dementia symptoms. * The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of diranersen. The study will be split into 2 parts. The 1st part is the Placebo-Controlled Period. The 2nd part is the Long-Term Extension (LTE) Period. The 2nd part of the study will help researchers learn about the long-term safety of diranersen, and how it affects the participant's daily life, thinking, and memory abilities in the longer term. A description of how the study will be done is given below. * After screening, participants will first receive either a low dose or high dose of diranersen, or a placebo, as an injection into the fluid around the spinal cord (cerebrospinal fluid). A placebo looks like the study drug but contains no real medicine. * Participants will receive diranersen or placebo once every 12 weeks or 24 weeks. * After 76 weeks of treatment in the Placebo-Controlled Period, eligible participants will move onto the Extension Treatment period, which will last 96 weeks. * In the extension period, participants who received placebo will be switched to high dose diranersen every 12 or 24 weeks. * Participants may be in the study for up to 201 weeks, or about 4 years. This includes the screening and follow-up periods. * Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. * After the screening period, most participants will visit the clinic every 6 weeks.

Conditions

  • Mild Cognitive Impairment Due to Alzheimer's Disease
  • Alzheimer's Disease Dementia

Interventions

  • DiranersenDrug

    Administered as specified in the treatment arm.

  • Diranersen-matching placeboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose response in Change From Baseline to Week 76 on the CDR-SBTime frame: Baseline to Week 76

Locations

138 sites in 17 countries. Site status is shown where the registry gives one.

  • Xenoscience Inc.

    Phoenix, Arizona

  • HonorHealth Neurology

    Scottsdale, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • Center for Neurosciences

    Tucson, Arizona

  • Mary S. Easton Center for Alzheimer's Disease Research, UCLA

    Los Angeles, California

  • PNS Clinical Research, LLC dba

    Orange, California

  • Stanford Hospital and Clinics

    Palo Alto, California

  • Sutter Institute for Medical Research

    Sacramento, California

  • University of California San Diego Medical Center

    San Diego, California

  • University of California San Francisco (PARENT)

    San Francisco, California

  • Rocky Mountain Movement Disorders Center, PC

    Englewood, Colorado

  • Charter Research, LLC

    Lady Lake, Florida

  • K2 Medical Research, LLC

    Orlando, Florida

  • Advent Health

    Orlando, Florida

  • Conquest Research

    Winter Park, Florida

  • Charter Research, LLC

    Winter Park, Florida

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Brigham and Women's Hospital Department of Neurology

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Lahey Clinic Medical Center - Burlington

    Burlington, Massachusetts

  • Boston Center for Memory

    Newton, Massachusetts

  • Neurological Associates of Albany, PC

    Albany, New York

  • Dent Neurologic Institute

    Amherst, New York

  • New York University Medical Center PRIME

    New York, New York

  • South Shore Neurologic Associates, P.C.

    Patchogue, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Duke University

    Durham, North Carolina

  • AMC Research, LLC

    Matthews, North Carolina

  • NeuroScience Research Center, LLC.

    Canton, Ohio

  • University of Cincinnati Physicians Group, LLC

    Cincinnati, Ohio

  • Butler Hospital

    Providence, Rhode Island

  • Neurology Clinic, PC

    Cordova, Tennessee

  • Neurology Consultants of Dallas, PA

    Dallas, Texas

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • EvergreenHealth

    Kirkland, Washington

  • Kingfisher Cooperative, LLC

    Spokane, Washington

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Southern Neurology

    Kogarah, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.